Novelix Pharmaceuticals Limited passed all three resolutions proposed at its 32nd Annual General Meeting held on September 30, 2026. The meeting, conducted via video conferencing, saw a total of 18,946,001 votes cast in favor across all agenda items.

The company reported that 73 shareholders attended the meeting through video conferencing, comprising 3 from the promoter group and 70 public shareholders. No shareholders attended in person or through proxy. The voting results were scrutinized by Bharat Khaniwal & Co., Company Secretaries, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting results summary

All resolutions were passed with a overwhelming majority. The table below details the voting outcome for each resolution:

Key resolutions passed

The first ordinary resolution involved the adoption of the standalone financial statements for the financial year ended March 31, 2026. This included the audited balance sheet, statement of profit and loss, cash flow statement, and reports from the Board of Directors and Statutory Auditors.

The second resolution addressed the re-appointment of Ms. Sridevi Belide as a Non-Executive Director. She retired by rotation and was eligible for re-appointment. The third resolution, a special resolution, approved the appointment of Mr. Gnana Prakash Gattu as Whole Time Director of the company.

What the numbers show

The voting data reveals a distinct pattern in shareholder participation and approval rates. While the promoter group held 15,457,733 shares, they voted 14,832,733 shares, representing 95.96% of their holding. Public non-institutional shareholders, holding 13,012,267 shares, voted only 4,119,278 shares, or 31.66% of their holding. Despite this disparity in participation rates, the final vote count remained identical across all three resolutions, with exactly 6,010 votes against each item. This suggests that the dissenting minority is consistent and likely represents a specific block of shareholders rather than varied opposition to different agenda items.

Novelix Pharmaceuticals Limited has scheduled its 32nd Annual General Meeting for September 30, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013.

The company announced the details in a communication to the BSE dated August 31, 2026. The Board of Directors fixed the cut-off date for determining voting eligibility as September 23, 2026.

Meeting and Voting Details

The Register of Members and Share Transfer Books will remain closed from September 24, 2026, to September 30, 2026. This closure ensures the determination of shareholders eligible to attend and vote at the AGM.

Remote e-voting will be available for shareholders who wish to cast their votes before the meeting. The e-voting period begins on September 27, 2026, at 9:00 am and ends on September 29, 2026, at 5:00 pm.

The company, formerly known as Trimurthi Limited, is headquartered in Hyderabad, Telangana. Venkateshwarlu Pulluru, Whole-time Director, signed the intimation.